Biofilms, the customized microniche.
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to Z Lewandowski.
Explore the source record for details and available documents.
In 18 patients with acute myocardial infarction admitted to the Cardiological Care Department within 6 hours after the onset of chest pain, before administration of drugs and then in the 2nd, 3rd, 5th and 7th day, the levels of glucose, pyruvate, lactate in venous blood, the lactate/pyruvate ratio (L/P) and pH, actual hydrocarbons, PCO2 and PO2 in capillary arterialized were determined. Depending on the clinical status at admission the patients were classified into 2 groups: I--without complications (I class according to Killip-Kimbal; n = 10), and II--with complications (II-IV class of cardiac failure according to Killip-Kimbal and/or complex ventricular arrhythmias e.i. III-V class according to Lown and heart block of Mobitz--type II and III degree; n = 8). None of the patients had diabetes, chronic respiratory tract diseases, renal failure and liver cirrhosis. The control group consisted of 11 healthy persons. On the first day of myocardial infarction, the significant increase of blood glucose, lactate, pyruvate, as well as significant decrease of blood pH, HCO3- and PO2, and non significant increase of L/P ratio were observed in both groups as compared to the control group. Also there were non significant difference of the glucose, lactate, pyruvate L/P ratio and pH, PCO2 and HCO3- values between the I and II group on the first day of the acute myocardial infarction, with exception of the PO2, which was significantly lower in the group II. In the following days an increase of PO2 was observed. Since this effect coincided with a decrease of lactate concentration (significant only in the group II) it could be concluded, that the observed decrease of the lactate concentration resulted from the higher supply of oxygen. The obtained results have shown, that increase of glycaemia values and decrease of PO2 values may be considered as biochemical markers for hemodynamic complications of acute myocardial infarction.
Bronchial provocation tests (histamine and acetylcholine) were performed in 40 subjects (30 of them with type 1 diabetes, and 10 healthy volunteers) without any history of respiratory disease, not smoking and not taking any bronchodilating drugs. Bronchial reactivity was assessed using PC20 estimated spirographically by measuring FEV1. The patients were classified into three groups according to the duration of the disease: group I (0-7 yrs), group II (8-15), and group III (> 15). In all the three groups diabetes was at a similar degree of compensation, as evaluated by the mean circadian glycaemia, serum fructosamine and the Schlichtkrull Mw index. Bronchial reactivity to acetylcholine and histamine decreased with diabetes duration. Reaction to acetylcholine was statistically lower after 7 years of diabetes. An autonomic neuropathy was detected within the respiratory system, parallel to tachycardia at rest, alteration of the Valsalva test and orthostatic hypotension.
UNLABELLED: The effect was studied of intraperitoneal intake of calcium on gentamicin nephrotoxicity in the rats. Two groups of Wistar were studied: G--in the first group gentamicin was injected in single daily dose 100 mg/kg b.w. subcutaneously, GCa--in the second group gentamicin was given s.c. and calcium intraperitoneal in single daily dose 45 mg Ca++/kg b.w. Results were evaluated after 3, 7, and 10 days of gentamicin injections and after ten days of gentamicin removal, Mean creatinine level after ten days of gentamicin administration was in G group 4.52 +/- 0.77 mg%, GCa--1.87 +/- 0.21 mg%, p less than 0.02, mean urea 192. 62 +/- 21.88 mg%, 77.09 +/- 8.68 mg%, p less than 0.01, serum calcium 8.39 +/- 0.15 mg%, 9.96 +/- 0.21 mg%, p less than 0.001, gentamicin in the renal cortex 384.68 +/- 67.62 micrograms/g tissue, 327.38 +/- 81.89 micrograms/g tissue p less than 0.05. Urinary calcium excretion was higher in the GCa group than in the group of control rats. Statistical differences were significant after 3 and 7 days of gentamicin intake. Differences were found also in the light and electron microscopic examination. CONCLUSION: Intraperitoneal calcium loading significantly reduced the gentamicin nephrotoxicity in the rats and lowered gentamicin level in the renal cortex of the rats.
The effect was studied of oral verapamil administration in two different doses on gentamicin nephrotoxicity. Three groups of Wistar male rats were studied: 1) treated with gentamicin 100 mg/kg b.w. subcutaneously, 2) treated with gentamicin s.c. and verapamil 5 mg/100 ml given in drinking water, 3) treated with gentamicin s.c. and verapamil 20 mg/100 ml. The examinations were performed after 3, 7 and 10 days of gentamicin administration and after 10 days of gentamicin removal. Oral verapamil administration in these doses did not prevent the renal functional and histological damage after gentamicin administration. Renal cortex content of gentamicin was lower only after 3 days of gentamicin administration (statistically significantly) in the verapamil groups.
The effect was studied of the converting enzyme inhibitor (captopril) on the gentamicin nephrotoxicity in rats. Captopril 25 mg/kg b.w. and gentamicin 100 mg/kg b.w. were injected subcutaneously in a single daily dose. Three groups of Wistar male rats were studied: 1) treated with gentamicin 3 and 7 days, 2) treated with gentamicin and captopril, 3) treated with captopril. The mean serum creatinine and urea levels and proteinuria in the second group were significantly higher than in the first one. Light and electron microscopy examinations demonstrated increased renal cortex damage in the second group. There were not differences between mean urea and creatinine levels in the third examined group and normal rats. Mechanism of gentamicin nephrotoxicity enhancement in the second group is unknown.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
INTRODUCTION: Activation of the humoral branch of the immunological response is currently believed to play an important role in pathogenesis of chronic allograft nephropathy. The impact of humoral alloreactivity, indicated by the presence of C4d deposits in peritubular capillaries of a renal allograft, on the development of chronic allograft nephropathy is a significant problem in transplantation. The aim of the study was to assess and correlate C4d expression in patients with chronic allograft nephropathy, with clinical and morphological variables, as well as to assess the impact of a change in immunosuppression regimen on posttransplant course and renal allograft morphology. PATIENTS AND METHODS: Twenty-six patients with chronic allograft nephropathy underwent biopsies to correlate C4d expression with clinical parameters and morphological findings. In all patients azathioprine was replaced with mycophenolate mofetil with additional CsA dose reduction in 12 patients. After 1 year, 14 protocol biopsies were performed. RESULTS: The frequency of C4d peritubular capillary deposition among patients with chronic allograft nephropathy was 30%. C4d expression appeared later after transplantation, was correlated with chronic allograft glomerulopathy and proteinuria but not other clinical or histological variables. C4d deposits displayed no independent impact on serum creatinine level. Proteinuria was significantly more reduced in the C4d(+) group. Progression of chronic morphological changes was significantly accelerated in the C4d(+) group. CONCLUSION: C4d peritubular capillary expression did not differentiate patients after immunosuppression enhancement, but it predisposed to progression of chronic morphological findings during 1-year observation.
Human herpesvirus-6 (HHV-6) is an opportunistic viral pathogen of emerging clinical significance in immunocompromised patients. We performed a seroepidemiological survey to test the relation between seroprevalence among donors and recipients for HHV-6 at three endpoints. Before transplantation sera obtained from cadaveric donors and from potential recipients were tested for IgG antibodies against HHV-6 using an enzyme-linked immunoassay. The group of recipient sera, including samples obtained before as well as 2, 4, 12, and 48 weeks after transplantation, were tested for anti-HHV-6 IgM antibodies using an indirect immunofluorescence assay. The statistical analysis was performed with the Cox proportional hazards models. The HHV-6 seronegative group (n = 11) compared with the HHV-6 seropositive group (n = 109) showed twice the risk of HHV-6 IgM seroconversion (RR = 2.24; P < .04), with a greater risk of fever, namely 3.8, which was on the verge of statistical significance. The opposite trend toward an association with acute rejection episodes was observed among HHV-6 seronegative patients (RR = 1.81). The presence of IgG antibody in the sera of donors to IgG seropositive recipients had no association with the occurrence of IgM seroconversion. In contrast, IgM antibodies to HHV-6 appeared in four of five seronegative patients who received allografts from IgG seropositive donors. These preliminary data suggest that the effects seem to be the consequence of HHV-6 transmission through a renal allograft.
INTRODUCTION: A growing number of patients are losing their kidney allografts due to glomerulonephritis. Although posttransplant IgA nephropathy (IgAN) is regarded as benign, it may lead to late allograft loss in a substantial number of patients. The aim of this study was to evaluate the influence of posttransplant IgAN on long-term transplantation outcomes, risk factors for progression of graft dysfunction, and effectiveness of therapeutic interventions. PATIENTS AND METHODS: We evaluated, potential risk factors for accelerated graft loss among 27 kidney allograft recipients with posttransplant IgAN, comparing graft survival in a control group matched for population and transplantation-related parameters. We evaluated the effectiveness of therapeutic interventions regarding immunosuppressive regimen, and hypertension control including angiotensin converting enzyme inhibitor (ACEI) usage with Kaplan-Meier, Cox proportional hazard plots, and log-rank tests in statistical analyses. RESULTS: Compared with the control group, patients with IgAN experienced a 6.57 higher risk for dialysis dependence (P < .01, 95% CI 1.4 to 30.83). The risk for accelerated graft loss in the course of IgAN was associated with graft dysfunction (RR = 2.16 for additional 1 mg/dL of serum creatinine at glomerulonephritis presentation; P < .03, 95% CI 1.2 to 4.36) and intense proteinuria as evidenced by a RR = 4.67 for the presence of the nephrotic syndrome (P < .05, 95% CI 0.95 to 22.8). Immunosuppression enhancement resulted in a significantly decreased risk of dialysis dependence, namely, RR = 4.76 (95% CI 1.12 to 20, P < .04). With ACEI treatment there was a tendency for a 2.8-fold decreased risk of dialysis dependence, without reaching statistical significance (P = .14). CONCLUSIONS: Patients with posttransplant IgAN may benefit from intensifying maintenance immunosuppression, which slows progression to end-stage graft dysfunction.
Explore the source record for details and available documents.